Methods for the re-derivation of diverse pluripotent stem cell-derived brown fat cells

a technology of brown fat cells and pluripotent stem cells, applied in the field of stem cell biology, can solve problems such as increasing age-dependent risk

Pending Publication Date: 2020-05-21
AGEX THERAPEUTICS INC
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

This patented technology describes various techniques used to clone specific types of somatic (Tg) interfering elements called regulators of signal transduction pathways involved in regulating certain biological processes like those related to hypertension, cardiovascular diseases, neurology disorders, renal failure, liver function abnormalities, cancer development, inflammatory response, autoimmune responses, arthritis, muscle degeneration, bone resorption caused by insulin defibrillate therapy, stroke, brain damage, cerebrum dementia, Parkinsonism, autophagy, etc., which can lead to severe complications including organ loss due to tissue fibers accumulation within organs associated therewith these proteins.

Problems solved by technology

The technical problem addressed in this patents relates to improving the ability to produce various forms of bone marrow precursors called platelet-like structures containing specific molecules involved in skeleton formation. This includes developing new sources of platelets for use in medical applications such as wound healing agents, cardiopathy prevention strategies, and promoting restoring normal functions after surgery on individuals who develop arteriosclerosis due to excessive accumulations of cholesterols. Additionally, it has been found that certain regulatory elements controlling cytokine production could affect both hormones and growth factor receptors expressed specifically in platelet membrane proteins, resulting in decreased activity towards inflammatory responses caused by oxystrophyseal pathways. These findings suggest ways to direct the different fate of placenta-related white adipoblasts (WO 2004; WESTRENGIDESCYNDM-1+CD36cells) toward more efficient targeted delivery of nutrient substance(nutritious ones) needed for effective management of adolescence states without causing harmful side effects upon living organisms.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods for the re-derivation of diverse pluripotent stem cell-derived brown fat cells
  • Methods for the re-derivation of diverse pluripotent stem cell-derived brown fat cells
  • Methods for the re-derivation of diverse pluripotent stem cell-derived brown fat cells

Examples

Experimental program
Comparison scheme
Effect test

example 1

of Effects of Adipocyte Differentiation Conditions Diverse Clonal Embryonic Progenitor Cell Lines

[0320]As shown in FIG. 1, many diverse clonal embryonic progenitor cell lines (Ctrl) expressed increased levels of the adipocyte marker FABP4 when cultured in HyStem beads supplemented with 10 ng / ml BMP4, 1.0 μM rosiglitazone, 2.0 nM triiodothyronine (T3), and for the last 4 hours prior to use, 10 μM CL316243 (Differentiated). As shown in FIGS. 2-4, only a subset of these diverse clonal hEP cell lines exhibited an up-regulation of UCP1, BETATROPHIN (also known as C19ORF80, LOC55908, and C19orf80) or ADIPOQ. While cultured fetal brown fat tissue (fBAT)-derived preadipocytes and subcutaneous adipose tissue (SAT)-derived preadipocytes showed only a minority of cells staining with the adipocyte marker Oil Red-O as described herein, and a minority of cells staining for UCP1, essentially all cells stained for the markers in differentiated cultures of the NP88 and NP110 lines (FIG. 5). As shown

example 2

Manufactured from Universal Donor cGMP Human ES Cell Lines

[0321]Clinical grade cGMP-compatible human ES cell lines are genetically modified to constitutively express CTLA4-Ig and PD-L1. (Z. Rong, et al, An Effective Approach to Prevent Immune Rejection of Human ESC-Derived Allografts, Cell Stem Cell, 14: 121-1.30 (2014) incorporated herein by reference. In brief, the human ES cell lines described by J. Crook et al, The Generation of Six Clinical-Grade Human Embryonic Stem Cell Lines, Cell Stem Cell 1, November 2007, are genetically-modified to constitutively express the genes CTLA4-Ig and PDL1 using a BAC-based targeting vector such as the HPRT BAC clone RP11-671P4 (Invitrogen) and the targeting vector is constructed using recombineering as described (Rong et al, A scalable approach to prevent teratoma formation of human embryonic stem cells, J. Biol. Chem. 287: 32338-32345; Song et al, Modeling disease in human ESCs using an efficient BAC-based homologous recombination system, Cell St

example 3

ization of Additional Diverse Embryonic BAT Cell Progenitors Derived from hESCs

[0323]A number of specific human ES cell-derived clonal embryonic progenitor cell lines are disclosed for the first time herein. Specifically, these cell lines have been given the following designations: NP88, NPCC SM19, NPCC SM23, NPCC SM28, NPCC SM31, NPCC SM36, NP111 SM, NP77 EN, NP78 EN, NP80 EN, NP91 SM, NP92 SM, NP93 SM, NP85 EN, NP113 SM, NPCC SM27, and SK1 All clonal embryonic progenitor cell lines were derived from the pluripotent cell stem cell line Envy (Costa et al., The hESC line Envy expresses high levels of GFP in all differentiated progeny, NAT Methods 2(4): 259-260 (2005)) with the exception of line SK1 which was derived from hESC cell line H9 (WA09) using methods described under the heading “Novel Uses of Cells With Prenatal Patterns of Gene Expression”; U.S. patent application Ser. No. 11 / 504,047 filed on Nov. 21, 2006 and entitled “Methods to Accelerate the Isolation of Novel Cell Strai

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Timeaaaaaaaaaa
Timeaaaaaaaaaa
Timeaaaaaaaaaa
Login to view more

Abstract

Aspects of the present invention include methods and compositions related to the production and use of pluripotent stem cell-derived clonal embryonic progenitor cell types useful in the generation of cellular components of brown adipocyte tissue for research and therapy relating to applications in obesity, diabetes, and cardiovascular disease.

Description

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Owner AGEX THERAPEUTICS INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products